In adults on antipsychotic therapy who develop weight gain or metabolic syndrome, does treatment with GLP‑1 receptor agonists compared with placebo or standard care improve weight and metabolic outcomes?
Abstract
GLP-1 receptor agonists are promising in managing weight gain and metabolic syndrome linked to antipsychotic therapy, yet further research specific to this population is needed for definitive conclusions.
Fields of Study & Subjects
Pharmacology and Obesity Treatment
Schizophrenia research and treatment
Diabetes Treatment and Management
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 5 March 2026
- Language
- EN